^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    L1CAM (L1 cell adhesion molecule)

    i
    Other names: L1CAM, L1 Cell Adhesion Molecule, Neural Cell Adhesion Molecule L1, Antigen Identified By Monoclonal Antibody R1, N-CAM-L1, NCAM-L1, CAML1, CD171, MIC5, CD171 Antigen, N-CAML1, HSAS1, L1CAM, HSAS, MASA, SPG1, S10
    3d
    Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. (PubMed, Front Immunol)
    The lack of conservation between the human and murine SELPLG proteins likely accounts for the discrepancy between enhanced in vitro migration of SELPLG-deficient L1CAM-CAR T cells and their lack of improved efficacy in the mouse model. This underscores the need for more predictive human-relevant models to better preclinically evaluate CAR T cell function.
    Journal
    |
    L1CAM (L1 cell adhesion molecule) • SELP (Selectin P)
    8d
    Clinical and Molecular Characterization of KRAS-Mutated Renal Cell Carcinoma. (PubMed, Cancers (Basel))
    PRNRP represents a distinct KRAS-mutant RCC subtype with unique metabolic and genomic features linked to its distal nephron origin. This contrasts with the genomic complexity and aggressive clinical behavior observed in KRAS-mutant PRCC and URCC, highlighting the need for subtype-specific diagnostic criteria and therapeutic strategies.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • L1CAM (L1 cell adhesion molecule)
    |
    KRAS mutation
    |
    MSK-IMPACT
    16d
    L1CAM/CD171 expression in human tumors and its association with tumor phenotype. (PubMed, Acta Oncol)
    The results highlighted a small number of tumor entities that could be targeted by anti-L1CAM drugs, once these are proved to be sufficiently safe and efficient. L1CAM expression does not appear to confer an aggressive phenotype to affected cancer cells.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    21d
    Glioma angiogenesis phosphoproteome landscape and biomarker sets identified with phenome-centered multiomics toward 3P medical approaches. (PubMed, EPMA J)
    These findings provide concrete molecular targets for antiangiogenic therapy and establish clinically actionable biomarkers for glioma patient stratification in the 3PM framework. The online version contains supplementary material available at 10.1007/s13167-025-00428-1.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CAMK2D (Calcium/Calmodulin Dependent Protein Kinase II Delta) • HSPB1 (Heat shock 27kDa protein 1) • L1CAM (L1 cell adhesion molecule) • PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha) • MYLK (Myosin Light Chain Kinase) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • PRKAR2B (Protein Kinase CAMP-Dependent Type II Regulatory Subunit Beta)
    22d
    Evaluating metastatic risk in breast cancer through CTCs and L1CAM expression. (PubMed, Front Oncol)
    H-CTCs and L1CAM-positive CTCs serve as potential blood-based biomarkers for evaluating metastatic risk in BC. The combined detection of H-CTCs and L1CAM enhances preoperative prediction of lymph node metastasis and provides new insights into BC metastasis mechanisms.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    22d
    Clinical Significance of Soluble L1CAM Serum Levels in Patients with High-Risk Endometrial Cancer. (PubMed, Biomedicines)
    sL1CAM is associated with poor prognosis in high-risk EC and seems to be associated with platinum response in endometrioid tumors. These findings support its potential role as a biomarker to improve risk stratification, warranting validation in larger, prospective studies.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    23d
    Novel Blood-Based Biomarker Candidates in Screening for Colorectal Cancer. (PubMed, Clin Colorectal Cancer)
    Application of blood-based biomarker panels consisting of colorectal neoplasia-associated proteins seem to be potential predictors for early detection of CRC. Especially IL-8 could have a significant impact on future screening models, though further testing in true screening cohorts is needed.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • GDF15 (Growth differentiation factor 15) • CHI3L1 (Chitinase 3-like 1) • L1CAM (L1 cell adhesion molecule)
    23d
    Impact of immunohistochemistry-based molecular classification with conventional risk stratification on recurrence and survival outcomes in endometrial cancer. (PubMed, Int J Clin Oncol)
    Conventional risk classification combined with IHC classification using p53 and MMR is a cost-effective prognostic tool that enables risk stratification and personalized treatment decisions, even when genetic testing is unavailable.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    25d
    Conventional FLCN-mutated tumor: a retrospective study of 5 cases with emphasis on diagnostic challenges. (PubMed, Hum Pathol)
    Conventional FMTs are indolent tumors, harboring hybrids of likely multiple cell populations. These tumors are usually misdiagnosed as sporadic ChRCCs or ROs. The panel of CK7, CD117, FOXI1, and L1CAM is useful for the diagnosis of c-FMTs.
    Retrospective data • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • FLCN (Folliculin) • L1CAM (L1 cell adhesion molecule)
    30d
    Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer. (PubMed, bioRxiv)
    Safety analyses with mouse cross-reactive antibodies indicate a feasible therapeutic window. Our findings offer strong proof-of-concept to support the preclinical development of these novel L1CAM ADCs as therapeutic agents for advanced solid tumors.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    1m
    FOSL2-induced transcriptional activation of L1CAM promotes progression of lung adenocarcinoma via the PI3K/AKT/mTOR signaling pathway. (PubMed, Int Immunopharmacol)
    Treatment with the AP-1 inhibitor T5224 reduced proliferation of A549 cells. Moreover, knockdown of L1CAM attenuated the tumor-promoting effects of FOSL2 overexpression, indicating that L1CAM contributes to the oncogenic activity of FOSL2, possibly by mediating activation of the PI3K/AKT/mTOR signaling pathway.
    Journal
    |
    L1CAM (L1 cell adhesion molecule) • FOSL2 (FOS Like 2)
    1m
    Nicotinic acetylcholine receptors function with adhesion molecule SAX-7 to reverse cell orientation during migration. (PubMed, Dev Biol)
    LC reversal in response to excess ACh also required the L1 cell adhesion molecule (L1CAM), SAX-7, which is expressed by both VNC and LC. We propose that an increase in ACh signaling in the VNC and LC promotes stronger SAX-7 mediated adhesion of the LC to the ventral body wall, causing the LC to change directions from posterior to ventral facing.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)